Interferon-α versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours

Digestion

Volumn 57, Issue , 1996, Pages 84-85

  Faiss, S ^a   Scherubl H ^a   Riecken, E O ^a   Wiedenmann, Bertram ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Combination; Diarrhoea; Interferon ; Lanreotide; Metastases; Neuroendocrine; Octreotide; Serotonin; Somatostatin; Tumour

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; OCTREOTIDE; SOMATOSTATIN;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; GASTROINTESTINAL TUMOR; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; INTERFERON TYPE I, RECOMBINANT; OCTREOTIDE; PANCREATIC NEOPLASMS; PEPTIDES, CYCLIC; SOMATOSTATIN; STOMACH NEOPLASMS;

EID: 0029984983     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000201404     Document Type: Article

References (17)

1. Kvols LK: Therapy of malignant carcinoid syndrome. Endocrinol Metab Clin North Am 1989;18:557-568.
2. Vinik AI, Thompson N, Echkauser F, Mottari AR: Clinical features of carcinoid syndrome and the use of somatostatin analogue and its management. Acta Oncol 1989:28:389-402.
3. Obcrg K, Norheim I, Theodorsson E: Treatment of malignant midgut carcinoid tumours with the long-acting somatostatin analogue, octreotide. Acta Oncol 1991:30:503-507.
4. Arnold R, Benning R, Neuhaus C, Rollwage M, Trautmann ME: GEP endocrine tumours: Effect of sandostatin on tumour growth. State of the Art Meeting. Monte Carlo. Proc Sandostatin 1991. p 41.
5. Schcrubi H, Wicdenmann B, Riccken EO, Thomas F, Kommerell B, Rath U: Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide. Eur J Cancer 1994:6:1590-1591.
6. Kvols LK, Moertel CG, O’Connell MJ, Schutt AK, Rubin J, Hahn RG: Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986:315:663-666.
7. Wiedenmann B, Räth U, Rädsch R, Becker F, Kommerell B: Tumour regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995. Klin Wo-chenschr 1988;6:75-77.
8. Arnold R, Neuhaus C, Benning R, Schwcrk WB, Trautmann ME, Joseph K, Bruns C: Somatostatin analog Sandostatin and inhibition of tumour growth in patients with metastatic endocrine gastrocntcropancreatic tumours. World JSurg 1993; 17:511-519.
9. Anthony L, Johnson D, Hande K: Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 1993;32:217-223.
10. Faiss S, Scherübl H, Räth U, Bonath T, Rieckcn EO, Wiedenmann B: Ultra-high-dosc lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancrcatic tumours. Gastroenterology 1995:108(suppl): A465.
11. Heron I, Thomas F, Dero M: Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analogue BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993:76:721-727.
12. Obcrg K: Chemotherapy and biotherapv in neuroendocrine tumours. Curr Opin Oncol 1993:5:110-120.
13. Eriksson B, Oberg K: An update of medical treatment of malignant endocrine pancreatic tumours. Acta Oncol 1993;32:203-208.
14. Obcrg K, Eriksson B: The role of interferons in the management of carcinoid tumours Acta Oncol 1991;30:519-522.
15. Creutzfeldt W, Bartseh HH, Jacubaschke K, Stockmann F: Treatment of gastrointestinal endocrine tumours with alpha-interferon and octreotide Acta Oncol 1991:30:529-535.
16. Joensuu H, Katka K, Kujari H: Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide Acta Endocrinol (Copenh) 1992; 126:184-185.
17. Tiensuu Janson EM, Ahlstrom H, Andersson T, Oberg K: Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 1992: 28A: 1647-1650.